Using our new BL cell lines, we successfully established NSG-BL avatar mouse models that also demonstrate differential tumor kinetics, CD20 expression profiles, and responsiveness to rituximab in vivo, consistent with our in vitro studies. This evidence concerns the gene MS4A1 and Burkitt lymphoma.